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Abstract: One fundamental observation in cancer etiology is that the rate of malignancies 
in any mammalian population increases exponentially as a function of age, suggesting a 
mechanistic link between the cellular processes governing longevity and carcinogenesis. In 
addition, it is well established that aberrations in mitochondrial metabolism, as measured 
by increased reactive oxygen species (ROS), are observed in both aging and cancer. In this 
regard, genes that impact upon longevity have recently been characterized in S. cerevisiae 
and C. elegans, and the human homologs include the Sirtuin family of protein deacetylases. 
Interestingly,  three  of  the  seven  sirtuin  proteins  are  localized  into  the  mitochondria 
suggesting  a  connection  between  the  mitochondrial  sirtuins,  the  free  radical  theory  of 
aging,  and  carcinogenesis.  Based  on  these  results  it  has  been  hypothesized  that  Sirt3 
functions  as  a  mitochondrial  fidelity  protein  whose  function  governs  both  aging  and 
carcinogenesis  by  modulating  ROS  metabolism.  Sirt3  has  also  now  been  identified  as  a 
genomically  expressed,  mitochondrial  localized  tumor  suppressor  and  this  review  will 
outline potential relationships between mitochondrial ROS/superoxide levels, aging, and cell 
phenotypes permissive for estrogen and progesterone receptor positive breast carcinogenesis. 
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1. Introduction 
Mammalian  cells  express  proteins  that  protect  against  endogenous  and  exogenous  forms  of 
genotoxic stresses that induce genomic instability [1–3]. These proteins monitor the integrity of cellular 
metabolism as well as respond to stressful conditions by activating compensatory pathways [4–6]. An 
extension of this observation would be that the loss of function or genetic mutation of these fidelity 
proteins  creates  a  cellular  environment  that  is  permissive  for  the  development  of  tumors  [7–10], 
suggesting that these proteins also function as tumor suppressor genes (TSG) in the context of aging 
and metabolism [11]. Since it is unlikely that evolutionary pressure selected for proteins in mammalian 
cells to prevent carcinogenesis, these proteins are more likely fidelity proteins that have evolved over 
time to protect specific organelles from damage induced by agents that induce genotoxic stress. 
Genomic instability, a hallmark of cancer, is thought to be an early event in neoplastic transformation 
induced by genotoxic agents [12–14]. As such one of the paradigms in biology is that mammalian cells 
contain fidelity proteins that recognize DNA damage and subsequently initiate signaling cascades that 
maintain cellular processes to prevent the accumulation of genomic damage [1,15,16]. In this context 
the best known example of a tumor suppressor (TS) gene is p53, which senses cellular damage from 
multiple endogenous and exogenous genotoxic stresses, including ionizing radiation (IR), and induces 
reparative processes that prevent IR-induced genomic instability and carcinogenesis [10,17,18]. Thus, 
it has been proposed that the genomic instability contributes to cellular phenotypes that represent early 
events in the multi-step genetic, epigenetic, and metabolic processes contributing to carcinogenesis. 
Mitochondria may also contain specific fidelity proteins that sense organelle conditions and activate 
signaling pathways to maintain mitochondrial homeostatic poise [19,20]. One of the primary functions 
of the mitochondria is the generation of ATP and complex aerobic organisms utilize oxygen as an 
electron acceptor in respiration, as an extremely efficient method of generating ATP [13]. However, 
by-products of mitochondrial electron transfer reactions in aerobic cells result in the production of 
ROS (i.e., superoxide and hydrogen peroxide) from the incomplete reduction of dioxygen [21]. The 
accumulation of abnormally high levels of mitochondrial superoxide from any source can create a 
condition referred to as “oxidative  stress” that damages cells and  is thought to contribute to both 
carcinogenesis  and  aging  [22,23].  While  low  steady-state  levels  of  ROS  are  easily  tolerated  and 
perform necessary signaling functions to coordinate metabolic and genetic processes [13], abnormally 
high levels of ROS from any number of possible sources can damage cells [24,25] and create a cellular 
environment  permissive  for  genomic  instability  as  well  as  carcinogenesis  [2].  Thus,  it  has  been 
proposed that mitochondrial damage, from any of a number of causes, might result in increased ROS 
that are causative agents in the development of genomic instability [26–28]. Int. J. Mol. Sci. 2011, 12  6228 
 
2. Sirtuins as Fidelity or Tumor Suppressor Proteins 
Sirtuins  are  NAD
+  dependent  class  III  histone  deacetylases  which  are  present  from  bacteria  to 
humans [29,30]. Unlike traditional histone deacetylases, sirtuins dynamically deacetylate a variety of 
substrates  ranging  from  transcription  factors to metabolic  enzymes  as  well  as  histones  [31,32]. In 
addition, sirtuins require NAD
+ as a co-factor which makes them a metabolic sensor and connects their 
enzymatic activity to the energy and redox state of cells [33,34]. One theme that has emerged in the 
last several years is that aging, perhaps better defined as longevity, is a complex cellular process that 
appears to be regulated, at least in part, by a relatively new gene family referred to as sirtuins. Sirtuin 
genes are the human and murine homologs of the Saccharomyces cerevisiae Sir2 gene that has been 
shown to regulate both replicative and overall lifespan [3,4]. The sirtuin family genes also regulate 
longevity in C. elegans and D. melanogaster [35,36]. 
In lower organisms, sir2 plays a role in longevity by enhancing multiple mechanisms including but 
not limited to silencing of telomeres and sub-telomeric regions, silent mating type loci, and, crucially, 
the rDNA,  suppressing  formation of rDNA circles [36,37]. On the other hand,  mammalian sirtuin 
members  are  associated  with  numerous  physiological  roles,  such  as  stress  response,  regulation  of 
metabolism, gene silencing, and aging [38,39]. While it has not been shown that these genes determine 
longevity in mammals they do appear to regulate critical signaling networks, and following stress, 
several mice lacking one of the sirtuin genes develop illnesses that mimic those observed in older 
humans [36,40]. Thus, it has been proposed that the mammalian sirtuins play a significant role, at least 
in part, in directing the acetylome signaling network that has recently been shown to be critical in the 
regulating multiple cellular processes [41]. These proteins share a common 275-amino acid catalytic 
domain  and  are  localized  to the  nucleus  (SIRT1,  6,  and  7),  mitochondria  (SIRT3,  4,  and  5),  and 
cytoplasm (SIRT2), respectively [42]. Unlike histone deacetyl transferase the sirtuins primarily target 
cellular  proteins  other  than  histones  suggesting  these  proteins  are  critical  the  regulation  of  cell 
signaling networks similar to phosphatases and kinases [39,41]. Sirtuins therefore appear to function as 
signaling proteins that post-translationally alter the activity of downstream protein targets via acetylation. 
3. Sirtuins Monitor and Direct Cellular Metabolism and Stress 
Sirtuin  activity  can  be  increased  in  response  to  metabolic,  genotoxic,  oxidative,  and  osmotic 
stresses. These stress responses appear to link to aging [43–45], oxidative stress, and the free-radical 
theory  of  aging  (FRTA)  [46].  In this  model  it  is  proposed that there  is  a  mechanistic  connection 
between aberrant cellular ROS levels and aging. Thus, it was proposed that an organism ages due to 
the unrepaired accumulation free radical damage to critical biomolecules as a function of time [1,13]. 
For most biological structures, free radical damage is closely associated with oxidative damage [47,48]. 
Thus, this theory would predict that antioxidants or reducing agents, may limit oxidative damage to 
biological  structures  by  detoxifying  free  radicals  and  preventing  aging  and  age-related  human  
illness [21,49,50]. 
Sirtuins, including the  mitochondrial  sirtuin Sirt3, appear to respond to changes  in cellular and 
nutrient stress resulting in the activation of their deacetylase or ribosyltransferase activity resulting in a 
post-translational modification of downstream target proteins [20,50–53]. For example, it is now well 
established that Sirt3 deacetylation activity is activated by caloric restriction (CR) and fasting [20,50,53] Int. J. Mol. Sci. 2011, 12  6229 
 
and  this  induction  in  deacetylation  activity  also  appears  to  protect  against  the  development  of  
age-related human pathology including cancer induction [20,54]. While the mice lacking Sirt3 do not 
exhibit changes in life span it has been shown in human studies that SIRT3 expression levels has been 
found to be associated with higher longevity [55]. In this regard, CR is the most effective non-genetic 
intervention described to increase lifespan across a wide variety of phyla [56]. While this phenomenon 
has been appreciated for many decades, the exact mechanism(s) remain unclear. While this effect has 
not been directly demonstrated in humans, humans may undergo many of the same metabolic changes 
and experience the same health effects in response to CR as seen in lower organisms [57]. In fact, it 
can  be  argued  that  CR  may  be  the  single  best  method  identified  to  decrease  the  incidence  of 
developing cancer and CR clearly decreases intracellular ROS [58]. Since it is now well established 
that  CR  activates  sirtuins,  including  Sirt3,  it  seems  reasonable  to  suggest  a  potential  connection 
between sirtuins, cellular metabolism as measured by aberrant mitochondrial ROS, and age-related 
illness and pathologies including carcinogenesis. 
4. Sirtuins and Regulation of the Mitochondrial Acetylome 
The  sirtuins  appear  to  play  a  central  role,  at  least  in  part,  in  regulating  the  cellular  acetylome 
responding to endogenous and exogenous cell stress and nutrient distress [39,59]. Thus, is has been 
proposed that at least one function of the sirtuin gene family is the regulation and maintenance of the 
Metabolome  via  the  deacetylation  of  specific  downstream  target  proteins  that  direct  intracellular 
oxidation/reduction  pathways  [37,41].  Reversible  acetylation  of  lysine  is  a  post-translational 
modification that neutralizes the positive charge of this amino acid, potentially altering the 3-dimensional 
structure of a protein as well as its enzymatic function [60,61]. One well known example of this is the 
histone deacetylases (HDACs) and histone acetyltransferases (HATs) that regulate gene expression 
through the modification of histone and changes in chromatin remodeling [62]. 
In this regard lysine acetylation has recently emerged as an important, and perhaps the primary, 
post-translational modification employed to regulate mitochondrial proteins [63,64]. Several proteomic 
surveys have identified a disproportionately high number of acetylated proteins in the mitochondria 
and many of these proteins are associated with energy homeostasis [64,65]. Reversible acetylation  
of  lysines  that  alter  protein  structure  is  mediated  by  histone  deacetylases  (HDACs)  and  histone 
acetyltransferases (HATs) that regulate gene expression through the  modification of  histones [62]. 
Lysine  acetylation  is  also  involved  in  the  regulation  of  p53  which  appears  to  also  play  a  role  in 
mitochondrial redox regulation [66].  
Sirt3 is the primary mitochondrial deacetylase and genetic knockout of Sirt3 alter mitochondrial 
protein acetylation [67] including aberrant/decreased mitochondrial ATP levels in vitro and in vivo [68]. 
Based  on  these  results,  acetylation  of  mitochondrial  proteins  may  play  a  role  in  maintaining  and 
regulating  mitochondrial  metabolism  and  function.  Thus,  we  believe  it  is  a  logical  extension  to 
hypothesize that Sirt3 is a regulatory protein, maintaining mitochondrial homeostasis via changes in 
the  acetylation  of  metabolic  target  proteins.  This  idea  would  mechanistically  connect  a  metabolic 
sensing  and/or  signaling  protein,  such  as  Sirt3,  to  the  direct  regulation  of  mitochondrial  energy 
metabolism, ATP synthesis, detoxification of mitochondrial ROS, as well as other biological processes 
essential for proper mitochondrial function. Int. J. Mol. Sci. 2011, 12  6230 
 
5. Sirtuins, Mitochondrial ROS, and Carcinogenesis 
Since the rate of malignancies increases significantly as a function of age, several reports have 
suggested  a  potential  mechanistic  link  between  the  cellular  process  governing  longevity  and  the 
development of cancers [58,69]. In addition, it is well established that the mitochondria of tumor cells 
exhibit  aberrant  ROS  and  this  observation  has  been  suggested  to  account  for  the  high  degree  of 
genomic instability demonstrated in cancer cells [46,70]. It is also a fundamental hypothesis in cancer 
research that increased or aberrant cellular mitochondrial ROS is an early event in cell damage that 
results in the generation of genomic stability that, under specific cellular conditions, can results in 
dedifferentiation and carcinogenesis [12,13,71]. These observations suggest a potential mechanistic 
connection between mitochondrial function and carcinogenesis; however, until recently there were a 
lack of genetic models to investigate this hypothesis.  
Sirt3  appears to  be the  primary  mitochondrial  deacetylase  it  has  been  proposed that  Sirt3  may 
function  as  a  mitochondrial  fidelity  gene  [72,73].  We  hypothesized  that  critical  regulators  at  the 
crossroads between aging and  loss of Sirt3 deacetylase activity  may create a cellular environment 
permissive for age-related cancers [19]. Thus, six years ago we, and others, constructed mice lacking 
the mitochondrial Sirt3 gene to determine if Sirt3 is a fidelity gene and if loss of function would create 
an in vivo tumor permissive phenotype. 
Sirt3 is the mitochondrial matrix protein that is present in high amount in mouse kidney, heart, 
liver, and brown adipose tissues. Mice lacking Sirt3 do not display any significant observable acute 
physiological  abnormalities;  however,  they  have  a  large  number  of  acetylated  proteins  in  their 
mitochondria relative to wild-type mice [67,73]. However, when these animals or their cultured cells 
were  challenged  with  various  stress  factors,  such  as  oxidative  stressors,  chemical-hormonal,  or 
ionizing  radiation,  they  displayed  physiological  phenotypes  consistent  with  increasing  age.  These 
phenotypes  included  cardiac  hypertrophy  [51,74],  carcinogenesis  [20,75,76],  fatty  liver  [52,77], 
radiation-induced liver damage [50], and age-related hearing loss [54,78]. While it is unlikely that 
there is one all encompassing, overarching mechanism that underlie above-mentioned in vivo phenotypes, 
each of these publications identified increased cellular ROS as a potential underlying etiology and 
suggest a potential connection between the development of these pathologies and aberrant mitochondrial 
metabolism.  Therefore  these  results  support  the  hypothesis  that  excessive  levels  of  ROS  is  one 
mechanism of shortened life span and age-associated pathological conditions, as suggested by the free 
radical theory of aging [46,70]. 
6. SIRT3 Is a Genomically Expressed, Mitochondrial Localized TS Protein 
In this regard, Sirt3 was reported to protect cells against ROS by enhancing the activity of antioxidant 
defense  system,  suggesting  that  this  protein  could  be  a  crucial  mitochondrial  fidelity  protein  in 
response to oxidative stress [20,50,53,54]. Whereas Sirt3 deficiency was well tolerated in young mice 
in normal conditions, at ages greater than one year old Sirt3 knockout mice exhibited a deterioration 
liver mitochondrial DNA, lower ATP production, increase mitochondrial ROS including superoxide 
levels,  and  developed  ER/PR  positive  breast  malignancies  [20]. These  results  suggested that  Sirt3 
might function as a mitochondrial fidelity protein and loss of function of Sirt3 may establish cellular 
environment permissive for aberrant mitochondrial metabolism, oxidative stress, and carcinogenesis. Int. J. Mol. Sci. 2011, 12  6231 
 
In  this  regard,  Sirt3  knockout  mouse  embryonic  fibroblasts  (MEFs)  exposed  to  various  stress 
factors,  such  as  oxidative,  genotoxic  stress,  and  radiation  exposures  resulted  in  a  loss  of  contact 
inhibition.  The  Sirt3
−/−  MEFs  were  also  immortalized  and  transformed  by  infection  with  a  single 
oncogene suggesting that Sirt3 might function as an in vitro tumor suppressor. These results were 
confirmed when mice lacking Sirt3 spontaneously developed mammary tumors appearing at just over 
one  year  of  age.  Finally,  the  interrogation  of  human  breast  cancer  samples  as  measured  via:  (1) 
staining  for  protein  levels;  (2)  RT-PCR  for  RNA  levels;  and  (3)  genomic  analysis  all  showed  a 
statistically significant decrease in SIRT3 levels in tumor cells, as compared to normal tissue controls. 
As  such,  we  would  propose  that these  results  very  strongly  suggest that  SIRT3  is  a  genomically 
expressed, mitochondrially localized tumor suppressor protein [20]. In this regard, the Sirt3 knockout 
mice do not begin to develop mammary tumors until after 12 months of age the immunohistochemical 
staining  has  identified  these  tumors  as  well  differentiated  estrogen  (ER)  and  progesterone  (PR) 
receptor positive mammary tumors [20]. This result seems logical since these mice lack a gene that has 
been suggested to play a role in aging or, perhaps better stated, anti-aging, and receptor positive breast 
malignancies  are  most  common  in  post-menopausal  women  and  have  a  very  strong  statistically 
correlation with increasing age [58,69]. In fact breast cancer has a very specific age-related incidence 
that increases slowly until the mid 60’s when a significant increase in incidence is observed [58]. 
While  our  work  [20],  and  another  rigorously  done  manuscript  [75,76],  have  both  shown  that  
Sirt3  functions  as  a  TS,  the  detailed  mechanism  linking  Sirt3-mediated  mitochondrial  ROS  and 
carcinogenesis still remains to be fully determined. In this regard, the subcellular localization of Sirt3 
is in close proximity to the main source of ROS production and this renders Sirt3 in the ideal location 
for  the  protection  from  aging  and  age-associated  disorders  including  carcinogenesis.  Elevated 
mitochondrial oxidative stress was proposed to play a role, at least in part, for the development of 
breast cancers in humans [79,80] as well as the development of mammary tumors in the aged Sirt3 
knockout  mice.  Consistent  with  this  data,  human  breast  tissue  samples  also  displayed  increased 
mitochondrial superoxide levels and decreased Sirt3 expression and the Sirt3
−/− mouse hepatocytes [20] 
and cardiomyoctes [51,74] also showed significantly higher basal superoxide levels that were observed 
to further  increase when exposed to different types of exogenous cellular stress challenges. These 
results suggested, but did not prove, a direct connection between aberrant mitochondrial superoxide 
levels and the tumor permissive phenotype observed in mice and MEFs lacking Sirt3. 
A  more  convincing  argument  for  the  role  of  aberrant  mitochondrial  superoxide  levels  in  cells 
lacking Sirt3 was shown using duel infection experiments with lentivirus expressing MnSOD. MnSOD 
is the primary superoxide detoxification enzyme that converts superoxide to hydrogen peroxide that is 
finally converted to water by catalase [81]. In these tissue culture experiments, co-infection of lenti-
MnSOD not only decreased mitochondrial superoxide levels but also prevented immortalization of 
Sirt3
−/− MEFs by a single oncogene [20]. These experiments were confirmed using a MnSOD gene 
where lysine 122 was mutated to an arginine, MnSOD
122K-R, resulting in a constitutively active dominant 
positive  MnSOD protein  [50].  Co-infection of  lenti-MnSOD
122K-R  also  prevented  immortalization of 
Sirt3
−/− MEFs by a single oncogene. In contrast, co-infection with mutated dominant negative MnSOD 
gene, lenti-MnSOD
122K-Q, mimicking a constitutively acetylated lysine, failed to prevent immortalization 
by infection with a single oncogene [50]. Similar experiments have shown that MnSOD lysine 68 [82] 
and lysines 53 and 89 [53] also appear to be deacetylated by SIRT3 as well as alter MnSOD enzymatic Int. J. Mol. Sci. 2011, 12  6232 
 
activity. Finally, it has also shown that infection of a MnSOD dominant positive (lenti-MnSOD
122K-R) 
gene prevented tissue culture transformation with exogenous agents such as ionizing radiation as well 
as stress-induced increases in cellular ROS [50]. All these experiments strongly suggest that aberrant 
mitochondrial superoxide metabolism, at least in part, plays a significant role in the tumor permissive 
phenotype observed in cells lacking Sirt3. 
While  this  work,  as  well  as  that  recently  published  from  the  Guarente  and  Haigis  
laboratories  [75,76,83],  suggests  a  mechanistic  connection,  at  least  in  part,  between  aberrant  
mitochondrial superoxide metabolism and carcinogenesis it seems like factors other, such as HIF-1 
than metabolism are involved. For example, we now know that a variety of important metabolic and 
cell survival related mitochondrial targets of Sirt3 including acetyl-CoA synthetase [63,84], glutamate 
dehydrogenase  (GDH)  [84,85],  long-chain  acyl-CoA  dehydrogenase  (LCAD)  [46],  succinate 
dehydrogenase [86] and mitochondrial ribosome subunit MRPL10 [87]. Sirt3 has also be shown to 
have pro-apoptotic or anti-apoptotic effects on different cell types and at least on mechanism involves 
deacetylating Ku70 and consequently preventing the release of BAX into mitochondria [88]. Finally, 
several manuscripts have identified multiple mitochondrial proteins that contain proteins (Figure 1) 
with reversible acetyl lysine(s) and many of these have been shown to be altered in cancers [64,65,67]. 
Thus, similar to p53, aberrant regulation of several proteins in the mitochondrial acetylome may play 
some role in the cellular damage and tumor permissive phenotype observed in mice lacking Sirt3. 
Figure  1.  Proposed  model  describing  Sirt3  acetylation  and  subsequent  regulation  of 
downstream  target  proteins  enzymatic  activity.  Sirt3  is  localized  into  the  inner 
mitochondrial membrane and appears to be activated by agents that induce oxidative stress 
and  respond  to  aberrant  or  increased  mitochondrial  levels  of  superoxide.  Sirt3  has  
been shown to regulate the activity of other mitochondrial proteins including acetyl-CoA 
synthetase  [63,84],  glutamate  dehydrogenase  (GDH)  [84,85],  long-chain  acyl-CoA 
dehydrogenase (LCAD) [46], succinate dehydrogenase [86,87], and mitochondrial ribosome 
subunit MRPL10 [87,88]. Sirt3 has also be shown to have pro-apoptotic or anti-apoptotic 
effects on different cell types and at least on mechanism involves deacetylating Ku70 and 
consequently preventing the release of BAX into mitochondria [88,89]. 
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One  final  question  is  how  aberrant  regulation  of  the  mitochondrial  acetylome,  results  in 
spontaneous,  stress-induced  genomic  instability  and  can  loss  of  proteins  other  than  Sir3  result  in 
spontaneous genomic instability [1]. In this regard, a somewhat similar finding was recently reported 
in Saccharomyces cerevisiae by the Gottschling laboratory [90]. In this work it was shown that a 
reduction in the mitochondrial membrane potential resulted in a cellular crisis identified via a defect in 
iron-sulfur cluster (ISC) biogenesis, which is required for normal mitochondrial function. This crisis 
resulted  in  downregulation  of  ISC  protein  biogenesis  causing  genomic  instability,  suggesting 
mitochondrial  dysfunction  stimulates  nuclear  genome  instability  by  inhibiting  the  production  of  
ISC-containing proteins. 
Our results also suggest that increased mitochondrial superoxide levels, which exceed the ability of 
MnSOD  to  detoxify  superoxide,  may  escape  the  mitochondria  and  subsequently  increase  both the 
cytoplasmic and nuclear superoxide levels. However, this idea is controversial since many researchers 
believe  that  superoxide  cannot  move  out  of  the  mitochondria.  Thus,  can  superoxide  generated  in 
mitochondria enter the cytosol via passage through voltage dependent or independent channels in the 
mitochondrial membranes causing alterations in redox signaling in the cytosol, potentially contributing 
to genomic instability in the nucleus? The evidence supporting this hypothesis is mostly indirect using 
anion channel blockers such as DIDS (4,4'-diisothiocyanatostilbene-2,2'-disulfonate) [91,92] or other 
methods  [93].  While  this  review  cannot  answer  this  controversy,  at  least  one  mechanism  for  the 
increased  genomic  instability  in  mice  and  MEFs  lacking  Sirt3  appears  to  involve  increased 
mitochondrial superoxide levels that use either existing ISC or other membrane channels to escape into 
cellular organelles outside of the mitochondria. 
7. Conclusions 
One  fundamental  observation  in  eukaryotic  biology  is  that  mammalian  cells  contain  fidelity 
proteins  that  function  to  monitor  the  integrity  of  critical  intracellular  processes,  and  deletion  or 
mutation of the corresponding genes results in a cellular environment permissive for the accumulation 
of damage [10,11,94]. Thus, it seems like a logical extension that the mitochondria would also contain 
fidelity proteins to maintain the integrity of the mitochondria. In this regard, loss of Sirt3 results in a 
series of stress and/or aging-related murine phenotypes including receptor positive breast cancer [20], 
fatty  liver  [52,77],  insulin  resistance  [52],  cardiac  hypertrophy  [51,74],  radiation-induced  liver 
steatosis [50], and age-associated hearing loss [54]. While it may be premature to make a cause and 
effect connection between age-related pathologies and alteration in mitochondrial ROS it seems likely 
that aberrant mitochondrial ROS plays a role, at least in part, in these murine phenotypes. Finally, it 
also  seems  clear  that  Sirt3  is  a  mitochondrial  localized  tumor  suppressor  or  fidelity  protein  and 
identifying  the  downstream  deacetylation  targets  of  Sirt3  will  lead  to  better  understanding  of 
mechanism linking mitochondrial fidelity, carcinogenesis, and aging. 
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